StockData

Kura Oncology vs Prelude Therapeutics

KURA and PRLD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KURA and PRLD compare

Kura Oncology is the larger company, worth 2.5 times as much as Prelude Therapeutics ($666M against $265M).

Prelude Therapeutics keeps more of each dollar of sales as profit, with a net margin of −270% compared with −369% at Kura Oncology.

Prelude Therapeutics scores higher on the StockData Score (8 against 1 for Kura Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKURAPRLD
Size and price
Market cap$666M$265M
Share price$7.49$3.32
Change, 1 year−33.2%118%
Change, 5 years−46.5%−76.3%
Beta (5Y)2.301.44
Employees26079
StockData Score
Total score18 (better)
Valuation score01 (better)
Growth score01 (better)
Performance score01 (better)
Health score15 (better)
Dividend score00
Valuation
P/S8.4× (better)11.8×
P/B37.1×2.0× (better)
FCF yield−13.4%−12.6% (better)
Fair value–$2.14
Margin of safety–−55.2%
Growth
Revenue growth (TTM)–220%
Profitability
Operating margin−394%−301% (better)
Net margin−369%−270% (better)
FCF margin−112% (better)−148%
Return on equity−225%−57.7% (better)
Financial health
Debt / equity0.55 (better)0.00
Interest coverage−227.1×–
Current ratio3.604.07 (better)
Altman Z-score−3.56−2.69 (better)
Piotroski F-score13 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions98.0%62.2%
Held by insiders2.7%40.5%
Insider net buying, 12 months$512K$25.0M (better)
Short interest, % of float14.6%8.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.